VEGFR TKI (Vacular endothelial growth factor receptor tyrosine kinase inhibitor, VEGFr-TKI)

All ESMO 2014 abstracts with reference to VEGFR TKI (Vacular endothelial growth factor Receptor tyrosine kinase inhibitor, VEGFr-TKI) are listed below

• 490P - Combining cytotoxic chemotherapy with antiangiogenic agents and complete responses in cancer patients: A meta analysis of published trials
• 533P - BATON-CRC: A phase 2 randomized trial comparing tivozanib (tivo) + mFOLFOX6 with bevacizumab (bev) + mFOLFOX6 in stage IV metastatic colorectal cancer (mCRC)
• 836P - Treatment and outcome(s) of a large cohort of poor risk metastatic renal cell carcinoma (prRCC) patients (pts)
• 845P - Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Updated results of a pooled analysis of noninterventional studies
• 849P - Real life efficacy and safety of axitinib (AXI) in patients with renal cell carcinoma (RCC): Results from the Spanish compassionate use program
• 1591P - Translational study for mechanisms of synergy and toxicity of tivozanib in combination with capecitabine in a population-based murine tumor model